In 2016, remdesivir demonstrated middling antiviral properties against Zika, but the disease disappeared before the expensive non-remedy got traction.8 After the Zika threat vanished, NIAID put some $6.9 million into identifying a new pandemic against which to deploy remdesivir. In 2018, Gilead entered remdesivir in a NIAID-funded clinical trial against Ebola in Africa.
